Stay updated on Glycine Supplement for Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Glycine Supplement for Severe COVID-19 Clinical Trial page.

Latest updates to the Glycine Supplement for Severe COVID-19 Clinical Trial page
- ChecktodayChange DetectedThe page has removed a citation regarding the clinical features of patients infected with the 2019 novel coronavirus in Wuhan, China, which is a significant loss of core content.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed information about a clinical trial studying glycine as a treatment for severe COVID-19, while retaining the trial's basic structure and location. The revision number has also been updated.SummaryDifference16%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
Stay in the know with updates to Glycine Supplement for Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Glycine Supplement for Severe COVID-19 Clinical Trial page.